` UCM (Uscom Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

UCM
vs
S
S&P/ASX 300

Over the past 12 months, UCM has underperformed S&P/ASX 300, delivering a return of -63% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
UCM vs S&P/ASX 300

Loading
UCM
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
UCM vs S&P/ASX 300

Loading
UCM
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
UCM vs S&P/ASX 300

Loading
UCM
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Uscom Ltd vs Peers

S&P/ASX 300
UCM
ABT
ISRG
BSX
SYK
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Uscom Ltd
Glance View

Market Cap
3m AUD
Industry
Health Care

Uscom Ltd. engages in the development, design, manufacture, and marketing of non-invasive cardiovascular and pulmonary medical devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-10. The firm manages a network of distribution partners across the world for the sale of its equipment to hospitals and other medical care locations. Its geographic segments include Singapore, Australia, China, South East Asia, Europe and the United States. The firm has approximately three practice suites of devices in the field of cardiac, vascular and pulmonary monitoring, including the USCOM 1A, which is an hemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment, USCOM BP+, which is a supra systolic oscillometric Central Blood Pressure monitor that measures blood pressure and blood pressure waveforms only previously available using cardiac catheterization, and the Uscom SpiroSonic spirometers, which is a digital pulmonary testing device.

UCM Intrinsic Value
0.017 AUD
Undervaluation 31%
Intrinsic Value
Price
Back to Top